Skor Kualitas, Nilai, dan Momentum
Kartu ini menunjukkan skor Kualitas, Nilai, dan Momentum untuk perusahaan tersebut.
Laporan Laba Rugi: Pendapatan, Laba Operasional, Laba Bersih
- Nilai operating income untuk Relmada Therapeutics, Inc. per 2025 Jun 30 adalah -70.52 MM.
- Nilai net income untuk Relmada Therapeutics, Inc. per 2025 Jun 30 adalah -67.81 MM.
Period End (TTM) | Revenue (MM) | Operating Income (MM) | Net Income (MM) |
2025-06-30 | -70.52 | -67.81 | |
2025-03-31 | -79.12 | -75.71 | |
2024-12-31 | -83.89 | -79.98 | |
2024-09-30 | -91.64 | -86.49 | |
2024-06-30 | -91.33 | -86.76 | |
2024-03-31 | -98.54 | -94.30 | |
2023-12-31 | -103.70 | -98.79 | |
2023-09-30 | -115.58 | -111.57 | |
2023-06-30 | -131.62 | -128.99 | |
2023-03-31 | -151.11 | -143.62 | |
2022-12-31 | -161.25 | -157.04 | |
2022-09-30 | -156.73 | -153.48 | |
2022-06-30 | -160.65 | -156.67 | |
2022-03-31 | -141.60 | -143.28 | |
2021-12-31 | -125.70 | -125.75 | |
2021-09-30 | -110.94 | -112.14 | |
2021-06-30 | -86.97 | -86.43 | |
2021-03-31 | -71.77 | -71.00 | |
2020-12-31 | -59.34 | -59.46 | |
2020-09-30 | -44.48 | -43.22 | |
2020-06-30 |
Laporan Laba Rugi: EPS
Period End (TTM) | Earnings Per Share Basic | Earnings Per Share Diluted |
2025-06-30 | ||
2025-03-31 | ||
2024-12-31 | -2.65 | |
2024-09-30 | -2.87 | -2.87 |
2024-06-30 | -2.88 | -2.87 |
2024-03-31 | -3.13 | -3.13 |
2023-12-31 | -3.28 | |
2023-09-30 | -3.71 | -3.71 |
2023-06-30 | -4.29 | -4.29 |
2023-03-31 | -4.78 | -4.77 |
2022-12-31 | -5.30 | |
2022-09-30 | -5.71 | -5.71 |
2022-06-30 | -6.60 | -6.60 |
2022-03-31 | -6.99 | -6.99 |
2021-12-31 | -7.16 | |
2021-09-30 | -6.66 | -6.65 |
2021-06-30 | -5.24 | -5.24 |
2021-03-31 | -4.42 | -4.42 |
2020-12-31 | -3.81 | |
2020-09-30 | -3.01 | -3.01 |
2020-06-30 | -2.34 | -2.34 |
Arus Kas: Operasi, Investasi, Pendanaan
- Nilai cash from operating activities untuk Relmada Therapeutics, Inc. per 2025 Jun 30 adalah -49.92 MM.
- Nilai cash from investing activities untuk Relmada Therapeutics, Inc. per 2025 Jun 30 adalah 49.53 MM.
- Nilai kas dari aktivitas pendanaan untuk Relmada Therapeutics, Inc. per 2025 Jun 30 adalah -0.34 MM.
Period End (TTM) | Cash From Operating Activities (MM) | Cash From Investing Activities (MM) | Cash From Financing Activities (MM) |
2025-06-30 | -49.92 | 49.53 | -0.34 |
2025-03-31 | -56.79 | 56.86 | -0.26 |
2024-12-31 | -51.76 | 51.56 | -0.04 |
2024-09-30 | -53.21 | 47.96 | 0.03 |
2024-06-30 | -48.18 | 35.67 | 0.12 |
2024-03-31 | -48.19 | 20.51 | 0.12 |
2023-12-31 | -51.66 | 50.45 | -0.10 |
2023-09-30 | -77.29 | 41.06 | 0.41 |
2023-06-30 | -92.52 | 68.75 | 0.98 |
2023-03-31 | -100.88 | 69.76 | 15.07 |
2022-12-31 | -103.80 | 19.73 | 45.02 |
2022-09-30 | -105.58 | -69.79 | 206.45 |
2022-06-30 | -99.63 | -73.84 | 206.06 |
2022-03-31 | -95.22 | -79.61 | 215.96 |
2021-12-31 | -91.87 | -54.12 | 187.94 |
2021-09-30 | -61.14 | 38.00 | 27.05 |
2021-06-30 | -52.73 | 15.08 | 28.50 |
2021-03-31 | -40.47 | 4.65 | 27.40 |
2020-12-31 | -27.81 | -34.45 | 28.47 |
2020-09-30 | -24.76 | -115.55 | 140.00 |
2020-06-30 |
Metrik Penilaian: PE, PriceToBook, PriceToTBV
- p/e untuk Relmada Therapeutics, Inc. pada 2025 Jun 30 adalah -0.26.
- p/libro untuk Relmada Therapeutics, Inc. pada 2025 Jun 30 adalah 0.89.
- p/tbv untuk Relmada Therapeutics, Inc. pada 2025 Jun 30 adalah 0.89.
- P/Book
- The current closing price divided by the book value per share.
- P/TBV
- The current price divided by the tangible book value per share.
Period End (TTM) | p/e | P/Book | P/TBV |
2025-06-30 | -0.26 | 0.89 | 0.89 |
2025-03-31 | -0.11 | 0.25 | 0.25 |
2024-12-31 | 0.29 | 0.29 | |
2024-09-30 | -1.17 | 1.65 | 1.65 |
2024-06-30 | -0.96 | 1.25 | 1.25 |
2024-03-31 | -1.40 | 1.62 | 1.62 |
2023-12-31 | -1.12 | 1.24 | 1.24 |
2023-09-30 | -0.71 | 0.82 | 0.82 |
2023-06-30 | -0.52 | 0.60 | 0.60 |
2023-03-31 | -0.43 | 0.48 | |
2022-12-31 | 0.64 | 0.64 | |
2022-09-30 | 5.66 | 5.66 | |
2022-06-30 | -3.97 | 2.71 | 2.71 |
2022-03-31 | -6.29 | 3.80 | 3.80 |
2021-12-31 | -5.60 | 8.64 | 8.64 |
2021-09-30 | -5.31 | 4.74 | 4.74 |
2021-06-30 | |||
2021-03-31 | -5.70 | 4.44 | 4.44 |
2020-12-31 | -6.64 | 3.74 | 3.74 |
2020-09-30 | -9.05 | 3.20 | 3.20 |
2020-06-30 | -12.77 | 2.90 | 2.90 |
Metrik Penilaian: EBitToEv, EBit3YrAvgToEv
- EBIT/EV untuk Relmada Therapeutics, Inc. pada 2025 Jun 30 adalah -4.03.
- EBIT (3 tahun) / EV untuk Relmada Therapeutics, Inc. pada 2025 Jun 30 adalah -5.18.
Period End (TTM) | EBIT/EV | EBIT (3y)/EV |
2025-06-30 | -4.03 | -5.18 |
2025-03-31 | -15.70 | -20.80 |
2024-12-31 | -6.99 | -9.23 |
2024-09-30 | -0.87 | -1.18 |
2024-06-30 | -1.06 | -1.43 |
2024-03-31 | -0.74 | -0.95 |
2023-12-31 | -0.94 | -1.06 |
2023-09-30 | -1.68 | -1.62 |
2023-06-30 | -3.12 | -2.80 |
2023-03-31 | -2.51 | -1.98 |
2022-12-31 | -2.43 | -1.63 |
2022-09-30 | -0.15 | -0.10 |
2022-06-30 | -0.27 | -0.17 |
2022-03-31 | -0.17 | -0.10 |
2021-12-31 | -0.18 | -0.10 |
2021-09-30 | -0.19 | -0.11 |
2021-06-30 | ||
2021-03-31 | -0.18 | -0.09 |
2020-12-31 | -0.15 | -0.08 |
2020-09-30 | -0.11 | -0.06 |
2020-06-30 | -0.08 | -0.05 |
Efektivitas Manajemen
- roa untuk Relmada Therapeutics, Inc. pada 2025 Jun 30 adalah -1.07.
- roe untuk Relmada Therapeutics, Inc. pada 2025 Jun 30 adalah -1.23.
- roic untuk Relmada Therapeutics, Inc. pada 2025 Jun 30 adalah -3.37.
- croic untuk Relmada Therapeutics, Inc. pada 2025 Jun 30 adalah -0.01.
- ocroic untuk Relmada Therapeutics, Inc. pada 2025 Jun 30 adalah -2.53.
Period End (TTM) | ROA | ROE | ROIC (Tingkat Pengembalian Investasi Modal) | CROIC | OCROIC |
2025-06-30 | -1.07 | -1.23 | -3.37 | -0.01 | -2.53 |
2025-03-31 | -0.95 | -1.11 | -2.25 | -0.01 | -1.46 |
2024-12-31 | -0.89 | -1.01 | -1.82 | -0.11 | -1.12 |
2024-09-30 | -0.79 | -0.86 | -1.41 | -0.20 | -0.78 |
2024-06-30 | -0.70 | -0.75 | -1.31 | -0.38 | -0.67 |
2024-03-31 | -0.65 | -0.70 | -1.16 | -0.02 | -0.61 |
2023-12-31 | -0.60 | -0.67 | -1.11 | -0.36 | -0.77 |
2023-09-30 | -0.60 | -0.66 | -1.16 | -0.20 | -0.83 |
2023-06-30 | -0.67 | -0.73 | -1.16 | -0.20 | -0.83 |
2023-03-31 | -0.70 | -0.75 | -1.14 | -0.13 | -0.80 |
2022-12-31 | -1.69 | -2.11 | -0.92 | 0.19 | -0.63 |
2022-09-30 | -1.72 | -2.16 | -0.92 | 0.19 | -0.63 |
2022-06-30 | -1.29 | -1.48 | -0.80 | 0.17 | -0.51 |
2022-03-31 | -1.21 | -1.38 | -0.68 | 0.20 | -0.45 |
2021-12-31 | -0.95 | -1.06 | -0.60 | 0.20 | -0.84 |
2021-09-30 | -0.89 | -0.71 | -1.54 | 0.05 | -0.54 |
2021-06-30 | -0.64 | -0.65 | -0.89 | -0.09 | -0.54 |
2021-03-31 | -0.62 | -0.63 | -0.78 | -0.09 | -0.44 |
2020-12-31 | -0.51 | -7.81 | -0.56 | -0.32 | -0.26 |
2020-09-30 | -5.08 | -7.23 | -0.35 | -0.00 | -0.21 |
2020-06-30 | -2.93 | -3.94 | -0.23 | 0.03 | -0.11 |
Gross Margins
- Margin Kotor
- The Gross Margin is the ratio of revenue left after substracting the Cost of Goods Sold. It is calculated as 1.0 - (Revenue - COGS ) / Revenue.
- Margin Keuntungan Bersih
- Margin Bersih (juga dikenal sebagai Margin Keuntungan) adalah rasio pendapatan yang tersisa setelah dikurangi Pendapatan Bersih. Perhitungannya adalah Pendapatan Bersih / Pendapatan.
- Margin Operasi
- Margin Operasi adalah rasio pendapatan yang tersisa setelah dikurangi Pendapatan Operasi. Perhitungannya adalah Pendapatan Operasi / Pendapatan.
Period End (TTM) | Margin Kotor | Margin Keuntungan Bersih | Margin Operasi |
2025-06-30 | |||
2025-03-31 | |||
2024-12-31 | |||
2024-09-30 | |||
2024-06-30 | |||
2024-03-31 | |||
2023-12-31 | |||
2023-09-30 | |||
2023-06-30 | |||
2023-03-31 | |||
2022-12-31 | |||
2022-09-30 | |||
2022-06-30 | |||
2022-03-31 | |||
2021-12-31 | |||
2021-09-30 | |||
2021-06-30 | |||
2021-03-31 | |||
2020-12-31 | |||
2020-09-30 | |||
2020-06-30 |
Pengenal dan Deskriptor
Kunci Indeks Pusat (CIK) | 1553643 |
Grupong Pang-industriya
SIC 2834 - Pharmaceutical Preparations |